205 related articles for article (PubMed ID: 36210219)
21. Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
Whittington MD; Campbell JD; Rind D; Fluetsch N; Lin GA; Pearson SD
Neurology; 2022 Mar; 98(9):e968-e977. PubMed ID: 35022306
[TBL] [Abstract][Full Text] [Related]
22. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
Villacorta R; Hay JW; Messali A
Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.
Ramjee L; Vurgun N; Ngai C; Patel M; Tremblay G
Clinicoecon Outcomes Res; 2023; 15():213-226. PubMed ID: 37020570
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
27. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
28. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
29. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
30. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
[TBL] [Abstract][Full Text] [Related]
31. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
Salcedo J; Bulovic J; Young CM
Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Cho SK; Hay JW; Barzi A
Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
[TBL] [Abstract][Full Text] [Related]
34. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Peng Y; She Z; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Dec; 38(12):5710-5720. PubMed ID: 34693504
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
38. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
[No Abstract] [Full Text] [Related]
39. A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Sorensen SV; Peng S; Monz BU; Bradley-Kennedy C; Kansal AR
Pharmacoeconomics; 2013 Jul; 31(7):589-604. PubMed ID: 23615895
[TBL] [Abstract][Full Text] [Related]
40. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
